StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

Investment analysts at StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a note issued to investors on Thursday. The brokerage set a “hold” rating on the stock.

Tonix Pharmaceuticals Stock Performance

Tonix Pharmaceuticals stock opened at $0.28 on Thursday. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. Tonix Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $12.48. The company’s 50-day moving average price is $0.25 and its 200-day moving average price is $0.33. The company has a market cap of $52.09 million, a PE ratio of -0.01 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. The business had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, equities research analysts forecast that Tonix Pharmaceuticals will post -17.63 EPS for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.